AI Driven Bloodless Blood Tests: GPx

AI Driven Bloodless Blood Tests
Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx
GPx: https://gpx.ai/

In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions
 and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has
 proven effective in reducing heart failure readmissions, but its use remains limited.

To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure
 exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients 
over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital 
biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and
early medical intervention.

Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National
 Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients
 starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto
 University, Kobe University, and Kochi University.

Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) 
potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our 
technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology)
 and to assess the potential for providing algorithm-based services for heart failure patients within Japan.